HPV6/11 Persistence and Treatment-Associated Immune Remodeling in Recurrent Respiratory Papillomatosis: A Cross-Cohort Transcriptomic Analysis
Viruses · 2026
DOI: 10.3390/v18101080 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2026. Verfasst von Natalia Jędruchniewicz und 4 weiteren Autor:innen. Beteiligte Einrichtung: Research and Development Center, Regional Specialist Hospital in Wroclaw, 51-124 Wroclaw, Poland. Hauptthemen laut MEDLINE: Papillomavirus Infections, Respiratory Tract Infections, Human papillomavirus 11, Human papillomavirus 6. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science Centre, National Science Centre, Poland.
Abstract (Originalsprache)
Recurrent respiratory papillomatosis (RRP), caused mainly by human papillomavirus types 6 and 11 (HPV6/11), can persist despite the absence of recognized systemic immunodeficiency. We reanalyzed three transcriptomic datasets using the same predefined immune-gene programs: paired papilloma and autologous laryngeal mucosa from 12 patients, single-cell RNA sequencing from papillomas of four RRP donors and pharyngopalatine mucosa from three controls, and paired papilloma samples from 17 patients before and after INO-3107, a DNA immunotherapy encoding HPV6/11 antigens and interleukin-12. In untreated tissue, cluster of differentiation 8 (CD8)- and natural killer (NK)-associated cytotoxic program scores were lower and the transforming growth factor beta (TGF-β) suppressive program score was higher, reproducing findings from the same cohort. The lower cytotoxic pattern was not reproduced within the recovered combined T-cell and NK-cell population, although no single-cell comparison remained significant after correction for multiple testing. After INO-3107, CD8- and NK-associated cytotoxic, T helper 1 (Th1)/interferon gamma (IFN-γ), and C-X-C motif chemokine receptor 3 (CXCR3)-associated trafficking program scores increased significantly, whereas TGF-β and M2-like suppressive programs showed no comparable statistically supported change. Together, these findings show that different components of the local immune response do not change in parallel and support a model of selective treatment-associated immune remodeling. This pattern may inform future biomarker and combination-treatment studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Research and Development Center, Regional Specialist Hospital in Wroclaw, 51-124 Wroclaw, Poland.
- Laboratory of Phage Molecular Biology, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 53-114 Wroclaw, Poland.
- Faculty of Medicine, Wroclaw University of Science and Technology, 50-370 Wroclaw, Poland.
- Institute of Human Genetics, Polish Academy of Sciences, 60-479 Poznan, Poland.
ORCID-Profile: Natalia Jędruchniewicz, Tomasz Klimek, Hanna Klimza, Krystyna Dąbrowska, Małgorzata Wierzbicka
Förderung
- National Science Centre
- National Science Centre, Poland
Zitieren
APA
Jędruchniewicz, N., Klimek, T., Klimza, H., Dąbrowska, K., & Wierzbicka, M. (2026). HPV6/11 Persistence and Treatment-Associated Immune Remodeling in Recurrent Respiratory Papillomatosis: A Cross-Cohort Transcriptomic Analysis. Viruses. https://doi.org/10.3390/v18101080
Vancouver
Jędruchniewicz N, Klimek T, Klimza H, Dąbrowska K, Wierzbicka M. HPV6/11 Persistence and Treatment-Associated Immune Remodeling in Recurrent Respiratory Papillomatosis: A Cross-Cohort Transcriptomic Analysis. Viruses. 2026. doi:10.3390/v18101080
BibTeX
@article{Jdruchniewicz2026,
author = {Jędruchniewicz, Natalia and Klimek, Tomasz and Klimza, Hanna and Dąbrowska, Krystyna and Wierzbicka, Małgorzata},
title = {HPV6/11 Persistence and Treatment-Associated Immune Remodeling in Recurrent Respiratory Papillomatosis: A Cross-Cohort Transcriptomic Analysis},
journal = {Viruses},
year = {2026},
doi = {10.3390/v18101080}
}
EUVIMED